This raised the potential to avoid the intolerable side effects of xerostomia while maintaining tumor control, and possibly moving PSMA-targeted RLT from a last resort to a more available radiotherapy for prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.